BioClinica ®, Inc., a global provider of clinical trial management services, announced today that JLL Partners and Ampersand Capital Partners, two leading middle market private equity firms, have completed their acquisition of BioClinica and CoreLab Partners and have combined the two companies under the name BioClinica.
This merger brings together two of the most experienced and trusted authorities in medical imaging management for clinical trials and creates a new standard in imaging core lab services, cardiovascular safety monitoring, and eClinical trial management solutions.
“The unification of BioClinica and CoreLab Partners will enhance the existing service quality and technological innovation supported by scientific and medical expertise that have long been hallmarks of these two companies,” said Mark Weinstein, who will lead the newly combined company as President and CEO. “This merger produces a stronger BioClinica that is better able to support pharmaceutical, biotechnology, and medical device development.”
Dan Agroskin, Managing Director of JLL Partners said, “JLL has spent a significant amount of time gaining an understanding of the pharmaceutical outsourcing sector and, as a result, we are pleased to have made these two acquisitions. This combination brings together two industry leading companies that we are confident will continue to deliver a strong service offering to their customers. We are excited by the growth potential of this newly formed platform, and we look forward to working with the talented management of BioClinica and CoreLab Partners as they continue to enhance their best-in-class capabilities.”